Neodymium: YAG lasers. An FDA report.
Analysis of data from four neodymium:YAG laser manufacturers submitted to the Food and Drug Administration (FDA) on over 17,000 cases indicate the procedure is safe and effective for cutting opaque posterior lens capsules. A successful opening in the pupillary membrane was achieved in 98% of the cases, and vision improved in 84% of the cases. Clinically significant risks include: a rise in intraocular pressure two to four hours after treatment, damage to the intraocular lens, and rupture of the anterior hyaloid face.
D006801:Humans; D007429:Intraocular Pressure; D007431:Intraoperative Complications; D053685:Laser Therapy; D007834:Lasers / Q000009:adverse effects; D007903:Lens Capsule, Crystalline / Q000601:surgery*; D007908:Lens, Crystalline / Q000601:surgery*; D009354:Neodymium; D011183:Postoperative Complications; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D009354:Neodymium